MindBio Therapeutics

MindBio is a biotechnology company focused on creating novel treatments for mental health conditions and is conducting the world's first at-home LSD microdosing human clinical trial. MindBio is a leader in the field of psychedelic microdosing and is advancing its drug and technology intervention programs through clinical trials. MindBio has developed a multidisciplinary platform to develop treatment methods and is involved in the development of psychedelics. It has completed a Phase 1 clinical trial involving 80 patients using microdosed Lysergic Acid Diethylamide (LSD). A Phase 2 clinical trial using microdosed LSD for patients with major depressive disorder is under development, and a Phase 2 clinical trial for advanced cancer patients experiencing existential distress is also in progress.